Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy
BCMA CAR-T-cell therapy exhibits favorable safety and efficacy in advanced R/R MM. Long-term follow-up confirmed durable responses in 50% of the advanced R/R MM patients who responded to the treatment (4/8).
Authors
- Li Jiang (ORCID: https://orcid.org/0000-0002-2007-2891)
- Yuanyuan Hao (ORCID: https://orcid.org/0000-0001-8573-5433)
- Zunmin Zhu (ORCID: https://orcid.org/0000-0002-6635-7454)
- Yanliang Bai
- Wei Li (ORCID: https://orcid.org/0000-0002-7526-6626)
- Zhen Wang (ORCID: https://orcid.org/0000-0003-2119-3131)
- Lei Zhang (ORCID: https://orcid.org/0000-0001-6302-8383)
- Wei Cheng (ORCID: https://orcid.org/0000-0001-5393-2926)
- Kai Sun (ORCID: https://orcid.org/0000-0003-3392-363X)
- Jing Yang (ORCID: https://orcid.org/0009-0004-8811-7234)
- Xiaoli Yuan (ORCID: https://orcid.org/0000-0003-0244-6674)
- Yuqing Chen (ORCID: https://orcid.org/0000-0002-9188-7406)
- Junwei Niu
- Zhoufeng Huang
Institutions
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1650568
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05